Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.70020 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Andrew Hastie und 5 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza A Virus, H7N9 Subtype, Influenza, Human, Antibodies, Viral. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Department of Health and Human Services, GSK, U.S. Department of Health and Human Services.
Abstract (Originalsprache)
Background
Influenza A/Hong Kong/125/2017 (H7N9) virus poses a pandemic risk owing to its evolving nature. This study evaluated the immunogenicity and safety of an AS03‐adjuvanted H7N9 vaccine in adults (18–64 years [younger] and ≥65 years [older]).
Methods
Participants (younger, n = 418; older, n = 420) were randomized to receive one of six adjuvanted vaccines (hemagglutinin [1.9 μg, 3.75 μg, and 7.5 μg] with AS03 A or AS03 B ) or placebo. The co‐primary objectives were to determine whether the adjuvanted vaccines elicit an immune response against the vaccine‐homologous virus 21 days after the second vaccine dose and to evaluate the safety of the vaccines.
Results
H7N9 AS03‐adjuvanted vaccines at various doses showed a humoral immune response but failed to meet CBER immunogenicity criteria. However, a trend of increased immune responses was observed with the AS03 A adjuvant versus the AS03 B adjuvant, particularly in older adults. In both age groups, injection site pain and fatigue occurred more frequently with adjuvanted vaccines. No reported serious adverse events were vaccine‐related.
Conclusions
This study did not achieve its primary objective at any dose level. The modest immune response to AS03‐adjuvanted vaccines, consistent with other studies using similar antigens, highlights the need for continued research for H7N9 pandemic preparedness. Trial Registration: NCT04789577 [ ClinicalTrials.gov ]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Rockville, Maryland, USA.
- GSK, Wavre, Belgium.
- GSK, Bangalore, India.
Förderung
- US Department of Health and Human Services
- GSK
- U.S. Department of Health and Human Services
- GlaxoSmithKline
Zitieren
APA
Hastie, A., Clarke, T., Germain, S., Ollinger, T., Lese, P., & Gupta, V. (2024). Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70020
Vancouver
Hastie A, Clarke T, Germain S, Ollinger T, Lese P, Gupta V. Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70020
BibTeX
@article{Hastie2024,
author = {Hastie, Andrew and Clarke, Tanya and Germain, Sophie and Ollinger, Thierry and Lese, Patricia and Gupta, Vinay},
title = {Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.70020}
}
EUVIMED